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Background
Highly active antiretroviral therapy (HAART) has dramatically changed the prognosis of HIV
disease, even in terminally ill patients. Although these patients may survive many years after the
diagnosis of AIDS if treated with HAART, some still die during treatment.
Methods
A retrospective study in a cohort of 481 HIV-infected patients treated with HAART between January
1998 and December 2005 was conducted to compare subgroups of long-term survivors (LTSs) and
patients who died during treatment.
Results
A total of 48 patients survived for more than 72 months (mean 83.8  standard deviation 5.6 months).
Thirty patients died during treatment (mean 35.3  25.0 months), of whom nine died from non-
AIDS-related causes, 18 died from AIDS-related causes, and three died as a result of HAART toxicity.
Although LTSs were significantly (P 5 0.015) younger at HAART initiation, age below 40 years was not a
predictor of long-term survival. The subgroups did not differ in the proportion of clinical AIDS cases at
HAART initiation, in the prevalence of hepatitic C virus (HCV) coinfection, or in pretreatment and end-of-
follow-up CD4 cell counts. In contrast, the viral load achieved during treatment was lower in the survivors
(P 5 0.03), as was the prevalence of hepatitis B virus (HBV) coinfection (P 5 0.03). Usage of either protease
inhibitor (PI)-containing regimens [odds ratio (OR) 9.0, 95% confidence interval (CI) 2.2–35.98, Po0.001]
or all three drug classes simultaneously (OR 7.4, 95% CI 2.2–25.1, Po0.001) was associated with long-
term survival. Drug holidays incorporated in structured treatment interruption (STI) were also associated
with a good prognosis (OR 14.9, 95% CI 2.9–75.6, Po0.001).
Conclusions
Long-term survival was associated with PI-based HAART regimens and lower viraemia, but not with
the immunological status either at baseline or at the end of follow up. STI when CD4 counts reach
350 cells/mL, along with undetectable viraemia, was a strong predictor of long-term survival.
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Introduction
It is well known that mortality rates have decreased and
survival of AIDS patients has been prolonged since the
introduction of highly active antiretroviral therapy
(HAART) in the year 1996 [1–8]. Observational cohort
studies have shown that the probability of staying alive on
HAART largely depends on adherence to treatment and the
degree of immunodeficiency at the time of HAART
initiation [4,5]. Wood et al. reported a crude mortality rate
of 7.1–15.2% after 4 years [4]. The probability of 4-year
survival was at least 80% for those with baseline CD4 cell
counts below 200 cells/mL, and above 90% for those with
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less advanced immunodeficiency. Results were far less
satisfactory in patients with poor adherence to treatment,
but even in those patients the probability of 4-year survival
was 54% [4]. An Italian study found a 62% probability of
15-month survival in patients diagnosed with AIDS and
started on antiretroviral therapy after 1996, i.e. in the
HAART era [6].
A number of patients on HAART die during treatment.
Causes of death include insufficient efficacy of treatment
and re-emergence of AIDS, with the development of new
AIDS-related illnesses, some of which may be fatal. HAART
toxicities, such as acute pancreatitis or lactic acidosis, may
also be life-threatening. Hyperlipidaemia, a common
HAART-associated side effect, may increase the risk for
potentially life-threatening cardiovascular events. Hepati-
tis C virus (HCV) infection was shown to progress more
rapidly in the context of HIV coinfection, with an increased
probability of earlier development of end-stage liver
disease. For this reason, end-stage liver disease has been
among the leading causes of death among HAART-treated
AIDS patients [9,10].
This retrospective study was conducted to analyse the
probability of, and factors associated with, long-term
survival as well as with mortality in HIV-infected patients
on HAART, treated in Serbia and Montenegro.
Methods
Patients
A cohort of 481 HIV-infected patients treated with HAART
at the HIV/AIDS Department of the Institute for Infectious
and Tropical Diseases in Belgrade between 1 January 1998
and 31 December 2005 was retrospectively analysed with
the aim of comparing the long-term survivors (LTSs),
defined as patients who survived for more than 6 years
after starting HAART, with patients who died during
HAART. Inclusion criteria consisted of HIV infection
(stages A–C according to the 1993 Centers for Disease
Control and Prevention (CDC) case definition criteria [11]),
initiation of HAART during the above-mentioned period,
and regular clinical and laboratory check-ups until the end
of the study period. HAART regimens were defined as
combinations of two nucleoside reverse transcriptase
inhibitors (NRTIs) with one or two protease inhibitors
(PIs) or one nonnucleoside reverse transcriptase inhibitor
(NNRTI). NRTIs available included zidovudine, lamivudine,
abacavir and D-drugs [didanosine (ddI) and stavudine
(d4T)], as tenofovir and emtricitabine have not yet been
registered in Serbia. PIs included nelfinavir, indinavir,
saquinavir and lopinavir/ritonavir, while NNRTIs included
efavirenz and nevirapine. Dual Pneumocystis carinii
pneumonia (PCP) and toxoplasmosis primary prophylaxis
was discontinued after patients achieved a sustained
immune response (CD4 cell count4200 cells/mL).
Consent for participation was obtained from all patients,
and the study was approved by the Clinical Centre of Serbia
Ethics Committee.
Clinical data
Clinical, immunological and virological responses to
HAART were evaluated every 2–4 months in a regular
disease history check-up and physical examination, along
with measurement of plasma viral load and CD4 cell counts
and routine haematological and blood chemistry analyses.
Additional diagnostic procedures included imaging tech-
niques such as radiography, ultrasonography, computed
tomography (CT) and magnetic resonance imaging (MRI) as
well as microbiological and histological examinations
when needed.
The structured treatment interruption (STI) strategy was
to discontinue HAART, if this was the patient’s choice,
when CD4 cell counts reached  350 cells/mL and plasma
viral loads become undetectable ( 50 HIV-1 RNA copies/
mL) and, conversely, to reintroduce the same successful
regimen, or another regimen that was potentially less toxic
or had different adverse events, when CD4 cell counts
dropped to  250 cells/mL. Thus, STI was offered to those
on successful HAART, particularly to those experiencing
drug toxicities.
All causes of death were diagnosed clinically, i.e. no
autopsies were performed.
Laboratory methods
CD4 cells were quantified by flow cytometry. Plasma HIV-1
RNA loads were measured using a quantitative reverse tran-
scriptase polymerase chain reaction (Ultrasensitive Assay
version 1.5; Roche Molecular Systems, Branchburg, NJ), which
has a lower limit of detection of 50 copies/mL (1.7 log10).
Statistics
All analyses were performed using an electronic database
organized in SPSS version 11.5 (SPSS Inc., Chicago, IL,
USA). Survival of patients on HAART was analysed by the
Kaplan–Meier survival method. Patients were classified
into two baseline CD4 cell count strata, i.e. those with
baseline CD4 cell counts below and above 100 cells/mL, as
we previously showed that a baseline CD4 cell count below
100 cells/mL was a predictor of immunological failure on
HAART [12]. For analysis of the differences between the
subgroups, nonparametric variables such as gender ratio,
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prevalence of hepatitis B virus (HBV) and HCV coinfection,
frequency of pretreatment clinical AIDS, and frequency of
pretreatment with mono or dual antiretroviral therapy
(ART), were compared by w2 or Fisher’s exact test (depending
on the number of patients in a particular analysis). Baseline
and end-of-follow-up mean CD4 cell counts and plasma
viral loads (log10), as well as age differences between
subgroups, were compared by one-way analysis of variance
(ANOVA). The level of significance was 0.05. Factors
associated with long-term survival on HAART were
analysed in a logistic regression model using both univariate
and multivariate approaches. Results are presented as odds
ratios (ORs) with 95% confidence intervals (95% CIs).
Results
Within the cohort of 481 HIV-infected treated patients, the
overall probability of surviving 80 months was 70%, with a
significant difference between those with a baseline CD4
cell count of below 100 cells/mL and all other patients (log
rank, P 5 0.044).
Of the 481 patients in the cohort, a total of 48 (22 female
and 26 male) patients had survived for more than 6 years.
The mean follow-up time was 83.8  5.6 months (range
74–95 months). Thirty patients (11 female and 19 male)
died during treatment, after a mean of 33.3  25.0 months
(range 3–100 months). Nine deaths were non-AIDS-related,
including end-stage liver disease, myocardial infarction
and non-AIDS-related malignancies in four, two and three
cases, respectively. HIV-related opportunistic tumours and
opportunistic infections were the cause of death in 18
cases. Of these, non-Hodgkin’s lymphoma and progressive
multifocal leucoencephalopathy were the cause of death in
five cases each, disseminated tuberculosis in four cases and
AIDS dementia complex in three cases, while one patient
died of wasting syndrome. Direct HAART toxicity, precisely
lactic acidosis, was fatal in three cases.
The patients’ characteristics are presented in Table 1.
LTSs were significantly (P 5 0.015) younger at the time of
HAART initiation; however, age below 40 years was not a
factor predictive of long-term survival (P 5 0.34). The
subgroups did not differ significantly (P 5 0.36) in the
proportion of clinical AIDS cases at treatment initiation, or
in baseline CD4 cell counts (P 5 0.06). However, the pro-
portion of patients with a baseline CD4 cell count of below
100 cells/mL was significantly (P 5 0.02) higher among
those who died. Univariate logistic regression analysis
revealed a more than 6-fold increased probability of dying
with AIDS in patients who presented with CD4 counts
below 100 cells/mL (OR 6.2, 95% CI 1.8–21.0, P 5 0.008).
Clinical AIDS at presentation was not a predictor of poor
prognosis (P 5 0.21). Moreover, the patient subgroups did
not differ in the end-of-follow-up CD4 count (P 5 0.3). In
contrast, LTSs achieved significantly lower viral loads than
patients who died (P 5 0.03). However, achieving undetec-
table viraemia was not a predictor of long-term survival
(P 5 0.21). In our series, neither HBV nor HCV coinfection
affected survival (log rank, P 5 0.1 and P 5 0.8, respectively).
Table 1 Characteristics of HIV-infected patients on highly active antiretroviral therapy (HAART) according to outcome
Variable LTSs Patients who died P
Number of patients 48 30
Number of female patients 22 11 0.2
Age (years) 36  8.2 46  19.7 0.015
Follow-up time (months) 83.85  5.56 35.34  24.99 o 0.001
Number of patients with clinical AIDS at baseline 28 17 0.36
Number of HBV-infected patients 3 7 0.03
Number of HCV-infected patients 23 12 0.33
Number of patients pretreated with mono and/or dual ART 42 16 0.008
Baseline CD4 count (cells/mL) 98.0  85.0 65.43  47.78 0.06
% of patients with baseline CD4 count  100 cells/mL 63.6 82.8 0.02
End-of-follow-up CD4 count (cells/mL) 361.6  210.2 309.0  237.2 0.3
% of patients who achieved CD4 count  350 cells/mL and
undetectable plasma viral load
72.9 13.3 0.015
Viral load achieved (log10 copies/mL) 1.8  0.58 2.42  1.31 0.03
Number of drugs taken 8.2  1.97 5.1  1.89 o 0.001
Number of patients ever taking three NRTIs 2 2 0.1
Number of patients ever taking two NRTIs 1 one NNRTI 19 9 0.2
Number of patients ever taking two NRTIs 1 one PI 35 17 0.04
Number of patients ever taking all three drug classes 29 10 0.02
Number of patients who underwent STI 33 2 0.003
Values shown are mean  standard deviation, unless otherwise specified.
ART, antiretroviral therapy; HBV, hepatitis B virus; HCV, hepatitis C virus; LTS, long-term survivor; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI,
nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; STI, structured treatment interruption.
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Use of regimens containing PIs and two NRTIs was
associated with long-term survival (OR 9.0, 95% CI 2.2–
35.98, Po0.001). Simultaneous use of all three drug classes
was also predictive of long-term survival (OR 7.4, 95% CI
2.2–25.1, Po0.001). LTSs took more drugs (Po0.001) and
had more regimen switching than patients who died. Use of
HAART composed of three NRTIs or NRTIs with an NNRTI
did not differ between subgroups, while the use of classic
HAART (two NRTIs 1 one PI) and HAART composed of all
three drug classes was significantly more common in the
LTS subgroup (P 5 0.04 and 0.02, respectively). Pretreat-
ment with mono and/or dual ART was much more common
among LTSs (P 5 0.008).
STI was offered to all patients in the cohort who met the
criteria described above (data not shown). Almost half of all
patients who achieved the most satisfactory response to
HAART (65 of 148) underwent STI; these patients were
followed up for 55.9  22.7 months, during which period
they experienced single or multiple drug holidays no
decreasing efficiency on further treatment efficacy. Of the
65 patients who underwent STI, 35 belonged to the subgroups
analysed here, 33 of whom eventually achieved long-term
survival, and two of whom subsequently died. Accordingly,
STI was a strong predictor of a good prognosis (OR 14.9, 95%
CI 2.9–75.6, Po0.001). As an effective measure to control
hyperlipidaemia and hepatitis, STI was mainly suggested to
patients with lipodystrophy and/or hyperlipidaemia, as well
as to those with severe hepatotoxicity. However, patients
who died of end-stage liver disease associated with HCV
infection did not undergo STI. Indeed, only one patient
among those with end-stage liver disease ever fulfilled the
immunological criteria for treatment interruption.
Discussion
The use since 1996 of HAART – a combination of at least
three drugs that includes either a PI or a NNRTI and two
NRTIs – has substantially improved the prognosis of HIV-
infected patients world-wide. HAART was introduced in
clinical practice in Serbia in 1997/1998. Up to that time,
most of our patients were on mono and/or dual ART.
Hence, 43% of patients in the cohort as a whole were
heavily pretreated. Patients in our subgroups were even
more likely to be heavily pretreated, with 87.5% of LTSs
and 53% of patients who died falling into this category, but
this is unsurprising in view of the fact that, to qualify as a
LTS, a patient had to have survived for at least 6 years,
meaning that he or she had to have been entered into the
study before 2000 (because new patients as of 1998 were
all immediately started on HAART). Thus, although
pretreatment with mono or dual ART was reported to
decrease the efficacy of HAART [13,14], this was not the
case in our series, probably because the pretreated patients
significantly more often took HAART regimens including
PIs and/or NNRTIs concomitantly with NRTIs [12].
Genotype resistance testing was not routinely performed;
thus, subsequent regimens were composed on the basis of
standards of care [15]. However, in this study we found
that, with appropriate sequencing of potent HAART regi-
mens, even patients with advanced infection had a 70%
probability of surviving for more than 6 years. This is
encouraging, particularly for resource-limited settings. In
such settings, D-drugs, which are associated with mito-
chondrial hepatotoxicity, are still in use, and it is not
uncommon for hepatotoxicity and lactic acidosis to occur
among patients with HCV coinfection.
An important finding in this study is the observed benefit
of STI. The question of whether STI is beneficial is currently
a major issue in HAART management. A major trial, the
Strategies for Management of Antiretroviral Therapy
(SMART) study, has been designed to determine which of
two different HIV treatment strategies would result in greater
overall clinical benefit [16]. Patients already on HAART were
randomly assigned to either a viral suppression strategy, in
which HAART was taken on an ongoing basis to suppress
viral load, or a drug conservation strategy, in which HAART
was started only when CD4 count dropped to below
250 cells/mL, with the aim of reducing drug side effects
and preserving treatment options. These patients took
HAART only until their CD4 count reached 350 cells/mL.
However, recently presented results of the SMART study
have revealed that this STI approach was associated with a
more than 2-fold increased risk of disease progression
relative to continuous HAART. For this reason, the SMART
Executive Committee recommended that enrolment into the
trial should be halted, and that it would be prudent to
reinitiate therapy in patients on drug holidays.
However, other studies have shown more favourable
results of STI. A study by Maggiolo et al., although carried
out in a series of patients with far less advanced infection,
showed STI to be safe, suggesting that further careful
prospective evaluation is needed to determine virological
and clinical outcomes over a long period [17]. Similarly,
the ISS PART study recently reported results from six
Italian and one Swedish infectious disease department
where patients on stable HAART whose nadir CD4 cell
counts were4250 cells/mL, and who had excellent immu-
nological and virological responses to HAART, were
included in a study of treatment interruptions [18]. HAART
was interrupted when CD4 counts reached 500 cells/mL,
and reintroduced when patients experienced a CD4 cell
count decline too350 cells/mL. This approach was rather
conservative, but still very useful for investigating the
model. The study showed that such treatment interruptions
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were safe and beneficial for patients with hyperlipidaemia;
in a number of patients with elevated cholesterol and
triglycerides, hyperlipidaemia returned to normal values
during treatment interruptions.
Similarly, our study showed that the STI strategy we
applied was a strong predictor of long-term survival.
However, unlike the SMART study, our STI strategy was not
guided only by CD4 cell count; instead, patients were
advised to undergo a treatment interruption if, along with a
CD4 cell count rise to  350 cells/mL, they achieved
undetectable viraemia. Of the patients who fulfilled these
criteria for STI, 65 have undergone STI, of whom 33 have
so far become LTSs (the remaining patients are still alive
but have not yet been followed for long enough). On the
other hand, very few patients (four) who subsequently died
while on HAART met the criteria for STI, but for some (two)
STI did not yet exist as a possible strategy at the time of
their management.
Taken together, the results of studies on STI suggest that
the STI approach to HAART may be justified. This is an
important therapeutic option: drug holidays are popular
with both patients and doctors, as drug conservation reduces
drug-associated toxicity; furthermore, the economic benefits
should not be neglected. Further studies are needed to
precisely define the criteria for the application of STI.
In conclusion, treatment initiated before patients experi-
ence profound immunodeficiency, use of PIs or simultaneous
use of all three drug classes, and treatment interruptions
when CD4 cell counts reach  350cells/mL and undetectable
viraemia is achieved seem to be associated with long-term
survival in patients with advanced HIV infection.
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